ClinicalTrials.gg
RecruitingNCT07287943Updated Nov 10, 2026

To Study the Efficacy and Safety of Medtronic 780G Insulin Pump in People With Gastroparesis and Type 1 Diabetes.

An interventional study of Medtronic 780G AID in Type 1 Diabetes and Gastroparesis Due to Diabetes Mellitus Type I, sponsored by Viral N. Shah. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Viral N. Shah · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Nov 10, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States — 190 open to participants now, 257 under way, 17 of them phase 3. Diabetes Mellitus, Type 1 · United States.

Planned enrollment
677th of 1,242
34 · median 40
Started
2026
with 61 others
No phase
614 of 1,458
99 open now
Primary completion
2027-04
later than 115 of 256 live
Registered
1,409th of 1,458
by date

Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, this one is the 677th largest by planned enrollment of the 1,242 interventional ones that give a count, is one of 62 that started in 2026, is one of 614 with no phase, reaches primary completion later than 115 of the 256 other live ones, and was the 1,409th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

190 of the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States are open now. Recruiting first, the newest first:

185 more — sign in →

All 190 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the efficacy and safety of Medtronic 780G automated insulin delivery system in adult persons with type 1 diabetes and gastroparesis.

03

Conditions studied

  • Type 1 Diabetes
  • Gastroparesis Due to Diabetes Mellitus Type I

Keywords

  • type 1 diabetes
  • gastroparesis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Diagnosis of T1D for at least 12 months with stable insulin regimen for at least 2 months
  • ≥8.0%
  • Diagnosis of gastroparesis per National Institute of Health (NIH) definition
  • Willing to use Medtronic 780G system either with Simplera CGM.
  • Ability to provide before any trial-related activities
  • If randomized to usual care group and on an insulin pump already, should be willing to use pump in manual mode only for the duration of the study

Exclusion criteria

Exclusion criteria

  • Age \<18 years
  • Current use of inhaled insulin (Afrezza)
  • Patients with T1D using any glucose lowering medications other than insulin at the time of screening
  • Pregnancy, breast feeding, or wanting to become pregnant
  • Current use (≥ 2 weeks of continuous use) of any steroidal medication, or anticipated long-term steroidal treatment (>4 weeks continuously), during the study period
  • History of gastric outlet obstruction or other gastrointestinal structural abnormalities
  • Estimated (eGFR) \<30 or on dialysis
  • History of SH in the previous 3 months
  • History of two or more episodes DKA requiring hospitalization in the past 12 months
  • Any medical (such as severe cardiovascular disease, , chronic liver disease) or psychosocial conditions that make a person unfit for the study at the discretion of investigators
  • Use of drugs within 5 half-lives prior to screening
  • Current use of cannabis or history of cannabinoid hyperemesis syndrome
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
34 participants (estimated)

Study arms

  • Experimental
    Medtronic 780G group

    Device: Medtronic 780G AID

  • No intervention
    Usual care

    Participants will continue either multiple daily injections or non-AID insulin pumps

Interventions

  • DeviceMedtronic 780G AID

    Participants in Medtronic AID treatment group will use it for three months

06

What researchers measure

Primary outcomes

  1. Time in Range (70-180 mg/dL)

    Percentage of time that sensor glucose values are within the target range of 70-180 mg/dL, as measured by continuous glucose monitoring (CGM).

    Time frame: Baseline to 3 months

Secondary outcomes

  1. HbA1c

    Change in glycated hemoglobin (HbA1c) measured using standard laboratory methods.

    Time frame: Baseline to 3 months

  2. Mean Sensor Glucose

    Mean sensor glucose value derived from CGM data.

    Time frame: Baseline to 3 months

  3. Time in Tight Target Range (70-140 mg/dL)

    Percentage of time that sensor glucose values are between 70 and 140 mg/dL (TTIR), measured by CGM.

    Time frame: Baseline to 3 months

  4. Time Above Range

    Percentage of time that sensor glucose values are \>180 mg/dL and \>250 mg/dL, measured by CGM.

    Time frame: Baseline to 3 months

  5. Time Below Range

    Percentage of time that sensor glucose values are \<70 mg/dL and \<54 mg/dL, measured by CGM.

    Time frame: Baseline to 3 months

  6. Glucose Variability

    Glucose variability assessed by the standard deviation (SD) of sensor glucose values from CGM data.

    Time frame: Baseline to 3 months

Other outcomes

  1. Severe Hypoglycemia

    Number of severe hypoglycemic events requiring assistance from another person.

    Time frame: 3 months

  2. Diabetic Ketoacidosis

    Number of diabetic ketoacidosis events defined by standard clinical criteria.

    Time frame: 3 months

07

Study locations

1 of 1 sites recruiting
  • Indiana University Health, Univeristy hospital
    Indianapolis, Indiana 46202, United States
    Recruiting
    • Zunera Tariq, MD · Contacttariqz@iu.edu · 317-278-0907
    • Viral Shah, MD · Contacttariqz@iu.edu · 317-278-6017
    • Viral Shah, MD · Principal investigator
    • Zunera Tariq, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No — Will be shared in future

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Apr 2027, 13 months after the start.

Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 13 months is below that.

Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

Primary completion moved twice since we started tracking on Sep 25, 2026: Nov 2026 → Apr 2027, last on Nov 10, 2026.

Completion moved twice since we started tracking on Sep 25, 2026: Dec 2026 → Apr 2027, last on Nov 10, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2025
First posted
Dec 17, 2025
StartActual
Feb 9, 2026
Primary completionEst.
Apr 1, 2027was Nov 2026
CompletionEst.
Apr 1, 2027was Dec 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 1, 2026→Apr 1, 2027
moved 2 times, Oct 7, 2026 – Nov 10, 2026
Study completion
Dec 1, 2026→Apr 1, 2027
moved 2 times, Oct 7, 2026 – Nov 10, 2026
Show all 2 updates
  1. Nov 10, 2026
    Primary completion Mar 1, 2027→Apr 1, 2027
    Study completion Jun 1, 2027→Apr 1, 2027
    + 1 other change: verification date
  2. Oct 7, 2026
    Primary completion Nov 1, 2026→Mar 1, 2027
    Study completion Dec 1, 2026→Jun 1, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07287943
Lead sponsor
Viral N. Shah
Collaborators
Medtronic
Responsible party
Viral N. Shah (Principal Investigator, Indiana University) — Sponsor-investigator
First posted
Dec 17, 2025
Start date
Feb 9, 2026
Primary completion
Apr 1, 2027 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

Sana Kalaji
Contact
skalaji@iu.edu
317-278-6017

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion